T77455
Burosumab
TargetMol
DETAILS
- Cas: 1610833-03-8
- Purity: 98%
- Category: Compound
DESCRIPTION
Burosumab(KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (CSHS) and tumor-induced osteochondrosis.
Lead Time: 4 - 5 weeks
Sign in to view pricingEquivalent Items
| ... Loading